[{"id":"40b2e445-7d09-4c36-a4dc-82af89409797","acronym":"","url":"https://clinicaltrials.gov/study/NCT05155033","created_at":"2021-12-13T14:12:41.079Z","updated_at":"2025-02-25T13:40:45.865Z","phase":"Phase 2","brief_title":"Phase II Trial of Combination Anti-PD-1 and Aldesleukin for Metastatic Melanoma and Renal Cell Carcinoma","source_id_and_acronym":"NCT05155033","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Proleukin (aldesleukin)"],"overall_status":"Recruiting","enrollment":" Enrollment 78","initiation":"Initiation: 08/18/2022","start_date":" 08/18/2022","primary_txt":" Primary completion: 09/01/2026","primary_completion_date":" 09/01/2026","study_txt":" Completion: 09/01/2027","study_completion_date":" 09/01/2027","last_update_posted":"2025-02-21"},{"id":"838ef8af-7db3-4078-892e-5e0008843be4","acronym":"","url":"https://clinicaltrials.gov/study/NCT01005745","created_at":"2023-12-09T15:40:19.931Z","updated_at":"2025-02-25T13:59:46.111Z","phase":"","brief_title":"Lymphodepletion Plus Adoptive Cell Transfer With High Dose IL-2 in Patients With Metastatic Melanoma","source_id_and_acronym":"NCT01005745","lead_sponsor":"H. Lee Moffitt Cancer Center and Research Institute","biomarkers":" IFNG","pipe":"","alterations":" ","tags":["IFNG"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • Proleukin (aldesleukin)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 19","initiation":"Initiation: 10/20/2009","start_date":" 10/20/2009","primary_txt":" Primary completion: 01/31/2014","primary_completion_date":" 01/31/2014","study_txt":" Completion: 03/01/2025","study_completion_date":" 03/01/2025","last_update_posted":"2025-02-19"},{"id":"f64ea437-bbba-4636-a7d3-e32dea593ac5","acronym":"","url":"https://clinicaltrials.gov/study/NCT05821686","created_at":"2023-04-20T14:03:53.032Z","updated_at":"2025-02-25T15:20:25.754Z","phase":"Phase 1/2","brief_title":"Efficacy of Interleukin-2 in Triple Negative Breast Cancer","source_id_and_acronym":"NCT05821686","lead_sponsor":"Nova Scotia Health Authority","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Proleukin (aldesleukin)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 10","initiation":"Initiation: 01/02/2026","start_date":" 01/02/2026","primary_txt":" Primary completion: 04/01/2028","primary_completion_date":" 04/01/2028","study_txt":" Completion: 04/01/2028","study_completion_date":" 04/01/2028","last_update_posted":"2025-02-12"},{"id":"81c78433-c4cf-4a3b-9d94-ce29fffcad16","acronym":"","url":"https://clinicaltrials.gov/study/NCT01701674","created_at":"2021-01-18T07:24:05.712Z","updated_at":"2025-02-25T14:33:43.754Z","phase":"","brief_title":"Ipilimumab With Lymphodepletion Plus Adoptive Cell Transfer and High Dose IL-2 in Melanoma Mets Pts","source_id_and_acronym":"NCT01701674","lead_sponsor":"H. Lee Moffitt Cancer Center and Research Institute","biomarkers":" BRAF","pipe":" | ","alterations":" BRAF mutation • BRAF V600 • BRAF wild-type","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation • BRAF V600 • BRAF wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Yervoy (ipilimumab) • cyclophosphamide • fludarabine IV • Proleukin (aldesleukin) • cyclophosphamide intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 13","initiation":"Initiation: 10/09/2012","start_date":" 10/09/2012","primary_txt":" Primary completion: 04/21/2016","primary_completion_date":" 04/21/2016","study_txt":" Completion: 09/08/2025","study_completion_date":" 09/08/2025","last_update_posted":"2025-02-10"},{"id":"71628f3d-27a7-487c-a8bd-86587a5fa22b","acronym":"","url":"https://clinicaltrials.gov/study/NCT00026312","created_at":"2023-11-21T19:15:23.482Z","updated_at":"2025-02-25T16:50:44.915Z","phase":"Phase 3","brief_title":"Isotretinoin With or Without Dinutuximab, Aldesleukin, and Sargramostim Following Stem Cell Transplant in Treating Patients With Neuroblastoma","source_id_and_acronym":"NCT00026312","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" MYCN • NCR3LG1","pipe":"","alterations":" ","tags":["MYCN • NCR3LG1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Proleukin (aldesleukin) • Qarziba (dinutuximab beta) • Unituxin (dinutuximab) • Leukine (sargramostim)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 1449","initiation":"Initiation: 10/18/2001","start_date":" 10/18/2001","primary_txt":" Primary completion: 01/12/2012","primary_completion_date":" 01/12/2012","study_txt":" Completion: 03/07/2025","study_completion_date":" 03/07/2025","last_update_posted":"2025-02-04"},{"id":"78abffa2-7b4c-493d-a391-404776dd9c0b","acronym":"","url":"https://clinicaltrials.gov/study/NCT01038778","created_at":"2021-01-18T04:04:38.458Z","updated_at":"2025-02-25T16:58:23.955Z","phase":"Phase 1/2","brief_title":"Entinostat in Combination With Aldesleukin in Treating Patients With Metastatic Kidney Cancer","source_id_and_acronym":"NCT01038778","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" mTOR","pipe":"","alterations":" ","tags":["mTOR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Jingzhuda (entinostat) • Proleukin (aldesleukin)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 47","initiation":"Initiation: 10/29/2009","start_date":" 10/29/2009","primary_txt":" Primary completion: 05/22/2019","primary_completion_date":" 05/22/2019","study_txt":" Completion: 07/30/2025","study_completion_date":" 07/30/2025","last_update_posted":"2025-02-03"},{"id":"1aa44e24-9704-4fe0-a608-34236855cfe0","acronym":"19-C-0017","url":"https://clinicaltrials.gov/study/NCT03745326","created_at":"2021-01-18T18:20:39.102Z","updated_at":"2024-07-02T16:34:38.005Z","phase":"Phase 1/2","brief_title":"Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12D Variant of Mutated RAS in HLA-A*11:01 Patients","source_id_and_acronym":"NCT03745326 - 19-C-0017","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" EGFR • PD-L1 • KRAS • ALK • NRAS • HRAS","pipe":" | ","alterations":" PD-L1 expression • KRAS mutation • NRAS mutation • KRAS G12D • EGFR expression • HRAS mutation • KRAS G12 • NRAS G12D • NRAS G12 • HLA-A*11","tags":["EGFR • PD-L1 • KRAS • ALK • NRAS • HRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • KRAS mutation • NRAS mutation • KRAS G12D • EGFR expression • HRAS mutation • KRAS G12 • NRAS G12D • NRAS G12 • HLA-A*11"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • Proleukin (aldesleukin) • anti-KRAS G12D mTCR PBL • cyclophosphamide intravenous"],"overall_status":"Recruiting","enrollment":" Enrollment 70","initiation":"Initiation: 05/16/2019","start_date":" 05/16/2019","primary_txt":" Primary completion: 12/01/2027","primary_completion_date":" 12/01/2027","study_txt":" Completion: 12/01/2028","study_completion_date":" 12/01/2028","last_update_posted":"2024-06-05"},{"id":"8219a865-ee1b-4147-b478-9542d52eab59","acronym":"","url":"https://clinicaltrials.gov/study/NCT02858310","created_at":"2021-01-18T14:01:47.880Z","updated_at":"2024-07-02T16:34:58.731Z","phase":"Phase 1/2","brief_title":"E7 TCR T Cells for Human Papillomavirus-Associated Cancers","source_id_and_acronym":"NCT02858310","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" HLA-A","pipe":" | ","alterations":" HLA-A*02","tags":["HLA-A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HLA-A*02"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • Proleukin (aldesleukin) • E7 TCR cells"],"overall_status":"Recruiting","enrollment":" Enrollment 180","initiation":"Initiation: 01/27/2017","start_date":" 01/27/2017","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 01/01/2026","study_completion_date":" 01/01/2026","last_update_posted":"2024-06-05"},{"id":"92f8d52f-8230-4bcf-832a-25726a2e7d8a","acronym":"","url":"https://clinicaltrials.gov/study/NCT03190941","created_at":"2021-01-18T15:44:01.911Z","updated_at":"2024-07-02T16:34:38.067Z","phase":"Phase 1/2","brief_title":"Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients","source_id_and_acronym":"NCT03190941","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" KRAS • ALK • NRAS • HRAS","pipe":" | ","alterations":" KRAS mutation • NRAS mutation • KRAS G12V • HRAS mutation • KRAS G12 • NRAS G12 • HLA-A*11 • NRAS G12V","tags":["KRAS • ALK • NRAS • HRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • NRAS mutation • KRAS G12V • HRAS mutation • KRAS G12 • NRAS G12 • HLA-A*11 • NRAS G12V"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • Proleukin (aldesleukin) • cyclophosphamide intravenous"],"overall_status":"Recruiting","enrollment":" Enrollment 110","initiation":"Initiation: 09/21/2017","start_date":" 09/21/2017","primary_txt":" Primary completion: 06/29/2027","primary_completion_date":" 06/29/2027","study_txt":" Completion: 06/29/2028","study_completion_date":" 06/29/2028","last_update_posted":"2024-06-05"},{"id":"9c16748b-c315-47c8-8692-ae028f1c0f22","acronym":"","url":"https://clinicaltrials.gov/study/NCT05194735","created_at":"2022-01-18T12:54:11.846Z","updated_at":"2024-07-02T16:35:00.596Z","phase":"Phase 1/2","brief_title":"Phase I/II Study of Autologous T Cells to Express T-Cell Receptors (TCRs) in Subjects With Solid Tumors","source_id_and_acronym":"NCT05194735","lead_sponsor":"Alaunos Therapeutics","biomarkers":" IFNG • IL6 • TNFA • IL2","pipe":" | ","alterations":" MSI-H/dMMR","tags":["IFNG • IL6 • TNFA • IL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Proleukin (aldesleukin)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 180","initiation":"Initiation: 04/04/2022","start_date":" 04/04/2022","primary_txt":" Primary completion: 11/30/2024","primary_completion_date":" 11/30/2024","study_txt":" Completion: 11/30/2024","study_completion_date":" 11/30/2024","last_update_posted":"2024-05-29"},{"id":"1da77410-a879-4bd0-ac76-26adfb53609a","acronym":"","url":"https://clinicaltrials.gov/study/NCT05989828","created_at":"2023-08-14T14:10:18.266Z","updated_at":"2024-07-02T16:35:01.088Z","phase":"Phase 1","brief_title":"A2-ESO-1 TCR-Engineered T Cells for Relapsed/Refractory Advanced or Metastatic NY-ESO-1 Overexpression Positive Triple Negative Breast Cancer","source_id_and_acronym":"NCT05989828","lead_sponsor":"University of Southern California","biomarkers":" HER-2 • PD-L1 • ER • PGR • CTAG1B","pipe":" | ","alterations":" HER-2 negative • PGR negative","tags":["HER-2 • PD-L1 • ER • PGR • CTAG1B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • PGR negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • Proleukin (aldesleukin) • NY-ESO-1 TCR"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 08/01/2024","start_date":" 08/01/2024","primary_txt":" Primary completion: 08/01/2026","primary_completion_date":" 08/01/2026","study_txt":" Completion: 08/01/2027","study_completion_date":" 08/01/2027","last_update_posted":"2024-05-24"},{"id":"310e9d9a-b69c-4442-97f5-d4d4ad2729a2","acronym":"NCI-2018-00918","url":"https://clinicaltrials.gov/study/NCT03449108","created_at":"2022-07-22T15:57:20.497Z","updated_at":"2024-07-02T16:35:02.803Z","phase":"Phase 2","brief_title":"LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas","source_id_and_acronym":"NCT03449108 - NCI-2018-00918","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" HER-2 • CD8 • CD28 • CD27","pipe":" | ","alterations":" CD8 expression • CD28 expression","tags":["HER-2 • CD8 • CD28 • CD27"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD8 expression • CD28 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Yervoy (ipilimumab) • cyclophosphamide • fludarabine IV • Proleukin (aldesleukin) • LN-145 • LN-145-S1"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 04/27/2018","start_date":" 04/27/2018","primary_txt":" Primary completion: 06/30/2025","primary_completion_date":" 06/30/2025","study_txt":" Completion: 06/30/2025","study_completion_date":" 06/30/2025","last_update_posted":"2024-05-17"},{"id":"bda79509-21d5-4671-9520-4c738fdfa0e8","acronym":"","url":"https://clinicaltrials.gov/study/NCT02027935","created_at":"2021-05-24T22:52:50.882Z","updated_at":"2024-07-02T16:35:04.435Z","phase":"Phase 2","brief_title":"CD8+ Antigen-Specific T Cells, Cyclophosphamide, Aldesleukin, and Ipilimumab in Treating Patients With Metastatic Melanoma","source_id_and_acronym":"NCT02027935","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" BRAF • IL2 • MLANA","pipe":" | ","alterations":" BRAF mutation • BRAF V600","tags":["BRAF • IL2 • MLANA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation • BRAF V600"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Yervoy (ipilimumab) • cyclophosphamide • Proleukin (aldesleukin) • cyclophosphamide intravenous"],"overall_status":"Completed","enrollment":" Enrollment 16","initiation":"Initiation: 01/22/2015","start_date":" 01/22/2015","primary_txt":" Primary completion: 04/12/2024","primary_completion_date":" 04/12/2024","study_txt":" Completion: 04/12/2024","study_completion_date":" 04/12/2024","last_update_posted":"2024-05-10"},{"id":"1e5ed3ad-651b-4d13-abb3-c07ebb2ff472","acronym":"","url":"https://clinicaltrials.gov/study/NCT04562129","created_at":"2021-01-18T21:47:59.777Z","updated_at":"2024-07-02T16:35:04.844Z","phase":"Phase 2","brief_title":"IL2 With Ipilimumab Followed by Nivolumab in Stage 3 or 4 Melanoma Patients","source_id_and_acronym":"NCT04562129","lead_sponsor":"H. Lee Moffitt Cancer Center and Research Institute","biomarkers":" BRAF • IL2","pipe":" | ","alterations":" BRAF mutation • BRAF V600","tags":["BRAF • IL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation • BRAF V600"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Yervoy (ipilimumab) • Proleukin (aldesleukin)"],"overall_status":"Recruiting","enrollment":" Enrollment 29","initiation":"Initiation: 09/24/2020","start_date":" 09/24/2020","primary_txt":" Primary completion: 09/01/2024","primary_completion_date":" 09/01/2024","study_txt":" Completion: 09/01/2029","study_completion_date":" 09/01/2029","last_update_posted":"2024-05-08"},{"id":"e96ac04f-d494-4797-b71d-2048e4719923","acronym":"","url":"https://clinicaltrials.gov/study/NCT03318900","created_at":"2021-01-18T16:23:25.179Z","updated_at":"2024-07-02T16:35:05.191Z","phase":"Phase 1/2","brief_title":"T-Cell Infusion, Aldesleukin, and Utomilumab in Treating Patients With Recurrent Ovarian Cancer","source_id_and_acronym":"NCT03318900","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" HLA-A • PRAME • COL6A3","pipe":" | ","alterations":" PRAME expression","tags":["HLA-A • PRAME • COL6A3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PRAME expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • Proleukin (aldesleukin) • utomilumab (PF-05082566) • cyclophosphamide intravenous"],"overall_status":"Completed","enrollment":" Enrollment 8","initiation":"Initiation: 07/16/2018","start_date":" 07/16/2018","primary_txt":" Primary completion: 12/20/2023","primary_completion_date":" 12/20/2023","study_txt":" Completion: 12/20/2023","study_completion_date":" 12/20/2023","last_update_posted":"2024-05-08"},{"id":"93d8c998-c05e-429c-9692-227cbaba07cb","acronym":"NK4AML","url":"https://clinicaltrials.gov/study/NCT04347616","created_at":"2021-01-18T21:02:03.736Z","updated_at":"2024-07-02T16:35:08.070Z","phase":"Phase 1/2","brief_title":"Natural Killer-cell Therapy for Acute Myeloid Leukemia","source_id_and_acronym":"NCT04347616 - NK4AML","lead_sponsor":"Radboud University Medical Center","biomarkers":" IL2","pipe":"","alterations":" ","tags":["IL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • Proleukin (aldesleukin) • oNKord (inaleucel)"],"overall_status":"Recruiting","enrollment":" Enrollment 23","initiation":"Initiation: 12/03/2020","start_date":" 12/03/2020","primary_txt":" Primary completion: 09/01/2025","primary_completion_date":" 09/01/2025","study_txt":" Completion: 09/01/2025","study_completion_date":" 09/01/2025","last_update_posted":"2024-04-23"},{"id":"2368e794-6a95-4b8e-bfab-f3ed9d06481c","acronym":"","url":"https://clinicaltrials.gov/study/NCT01955460","created_at":"2021-01-18T08:52:28.248Z","updated_at":"2024-07-02T16:35:08.687Z","phase":"Phase 1","brief_title":"Genetically Modified T-Cells Followed by Aldesleukin in Treating Patients With Stage III-IV Melanoma","source_id_and_acronym":"NCT01955460","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" NGFR • TGFA","pipe":" | ","alterations":" TILs","tags":["NGFR • TGFA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TILs"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • Proleukin (aldesleukin) • cyclophosphamide intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 15","initiation":"Initiation: 10/15/2014","start_date":" 10/15/2014","primary_txt":" Primary completion: 06/01/2024","primary_completion_date":" 06/01/2024","study_txt":" Completion: 06/01/2025","study_completion_date":" 06/01/2025","last_update_posted":"2024-04-19"},{"id":"0ad7e2a2-55da-4a09-ae90-1310e59dd275","acronym":"NCI-2018-01758","url":"https://clinicaltrials.gov/study/NCT03691376","created_at":"2021-01-19T16:42:01.861Z","updated_at":"2024-07-02T16:35:15.468Z","phase":"Phase 1","brief_title":"Genetically Engineered Cells (NY-ESO-1 TCR Engineered T Cells and HSCs) After Melphalan Conditioning Regimen in Treating Patients With Recurrent or Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer","source_id_and_acronym":"NCT03691376 - NCI-2018-01758","lead_sponsor":"Roswell Park Cancer Institute","biomarkers":" CTAG1B","pipe":" | ","alterations":" CTAG1B expression","tags":["CTAG1B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CTAG1B expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e melphalan • Proleukin (aldesleukin)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 4","initiation":"Initiation: 03/08/2019","start_date":" 03/08/2019","primary_txt":" Primary completion: 01/30/2021","primary_completion_date":" 01/30/2021","study_txt":" Completion: 01/24/2027","study_completion_date":" 01/24/2027","last_update_posted":"2024-03-11"},{"id":"323ff3de-ebe5-4dfb-87f7-504068340771","acronym":"","url":"https://clinicaltrials.gov/study/NCT06138587","created_at":"2023-11-18T22:15:34.208Z","updated_at":"2024-07-02T16:35:17.114Z","phase":"Phase 1","brief_title":"Preemptive CIML NK Cell Therapy After Hematopoietic Stem Cell Transplantation","source_id_and_acronym":"NCT06138587","lead_sponsor":"Dana-Farber Cancer Institute","biomarkers":" IL2","pipe":"","alterations":" ","tags":["IL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Proleukin (aldesleukin) • CIML NK"],"overall_status":"Recruiting","enrollment":" Enrollment 15","initiation":"Initiation: 01/24/2024","start_date":" 01/24/2024","primary_txt":" Primary completion: 02/28/2026","primary_completion_date":" 02/28/2026","study_txt":" Completion: 11/30/2026","study_completion_date":" 11/30/2026","last_update_posted":"2024-02-28"},{"id":"a555d72e-a833-4298-a799-b874d7c7606c","acronym":"","url":"https://clinicaltrials.gov/study/NCT00338377","created_at":"2021-01-18T01:10:12.317Z","updated_at":"2024-07-02T16:35:20.425Z","phase":"Phase 2","brief_title":"Lymphodepletion Plus Adoptive Cell Transfer With or Without Dendritic Cell Immunization in Patients With Metastatic Melanoma","source_id_and_acronym":"NCT00338377","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" IL2","pipe":"","alterations":" ","tags":["IL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • Proleukin (aldesleukin) • cyclophosphamide intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 1230","initiation":"Initiation: 02/01/2006","start_date":" 02/01/2006","primary_txt":" Primary completion: 02/28/2030","primary_completion_date":" 02/28/2030","study_txt":" Completion: 02/28/2030","study_completion_date":" 02/28/2030","last_update_posted":"2024-02-07"},{"id":"7ff4baf4-9627-40b5-906f-346088349ad5","acronym":"","url":"https://clinicaltrials.gov/study/NCT03068624","created_at":"2021-01-18T15:07:02.967Z","updated_at":"2024-07-02T16:35:22.311Z","phase":"Phase 1","brief_title":"Autologous CD8+ SLC45A2-Specific T Lymphocytes With Cyclophosphamide, Aldesleukin, and Ipilimumab in Treating Patients With Metastatic Uveal Melanoma","source_id_and_acronym":"NCT03068624","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" IL2","pipe":"","alterations":" ","tags":["IL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Yervoy (ipilimumab) • cyclophosphamide • Proleukin (aldesleukin) • cyclophosphamide intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 34","initiation":"Initiation: 09/08/2017","start_date":" 09/08/2017","primary_txt":" Primary completion: 12/31/2022","primary_completion_date":" 12/31/2022","study_txt":" Completion: 07/31/2025","study_completion_date":" 07/31/2025","last_update_posted":"2024-01-25"},{"id":"bee6568b-22ed-4400-bf51-3257dce9d370","acronym":"","url":"https://clinicaltrials.gov/study/NCT02306954","created_at":"2021-01-18T10:55:08.267Z","updated_at":"2024-07-02T16:35:22.281Z","phase":"Phase 2","brief_title":"Study of High Dose Interleukin-2 (IL-2) and Stereotactic Body Radiation (SBRT) in Patients With Metastatic Renal Cancer","source_id_and_acronym":"NCT02306954","lead_sponsor":"Providence Health \u0026 Services","biomarkers":" IL2","pipe":"","alterations":" ","tags":["IL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Proleukin (aldesleukin)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 84","initiation":"Initiation: 12/01/2014","start_date":" 12/01/2014","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 12/01/2026","study_completion_date":" 12/01/2026","last_update_posted":"2024-01-25"},{"id":"7442a163-6eec-47a9-bb41-9d083af1512d","acronym":"","url":"https://clinicaltrials.gov/study/NCT01857934","created_at":"2021-01-18T08:18:15.837Z","updated_at":"2024-07-02T16:35:23.492Z","phase":"Phase 2","brief_title":"Therapy for Children With Advanced Stage Neuroblastoma","source_id_and_acronym":"NCT01857934","lead_sponsor":"St. Jude Children's Research Hospital","biomarkers":" MYCN","pipe":" | ","alterations":" MYCN amplification","tags":["MYCN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MYCN amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • vincristine • topotecan • melphalan • mesna • Proleukin (aldesleukin) • busulfan • Unituxin (dinutuximab) • Leukine (sargramostim) • Neupogen (filgrastim) • cyclophosphamide intravenous • humanised dinutuximab (Hu14.18K322A)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 153","initiation":"Initiation: 07/05/2013","start_date":" 07/05/2013","primary_txt":" Primary completion: 10/21/2021","primary_completion_date":" 10/21/2021","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2024-01-15"},{"id":"4e9aa552-a12c-4da8-8240-a354eef4c428","acronym":"","url":"https://clinicaltrials.gov/study/NCT00968760","created_at":"2021-01-18T03:46:34.880Z","updated_at":"2024-07-02T16:35:25.752Z","phase":"Phase 1","brief_title":"CD19-specific T Cell Infusion in Patients With B-Lineage Lymphoid Malignancies","source_id_and_acronym":"NCT00968760","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" IL2","pipe":"","alterations":" ","tags":["IL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • etoposide IV • carmustine • melphalan • Proleukin (aldesleukin) • Depocyte (liposomal cytarabine)"],"overall_status":"Completed","enrollment":" Enrollment 34","initiation":"Initiation: 06/20/2011","start_date":" 06/20/2011","primary_txt":" Primary completion: 04/23/2020","primary_completion_date":" 04/23/2020","study_txt":" Completion: 04/23/2020","study_completion_date":" 04/23/2020","last_update_posted":"2023-12-19"}]